Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 373
- Registration Number
- NCT00274274
Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9
- Registration Number
- NCT00267683
Factor VIIa in Acute Intracerebral Haemorrhage
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 90
- Registration Number
- NCT00266006
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5652
- Registration Number
- NCT00264901
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
Effect of Growth Hormone in Children With Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 173
- Registration Number
- NCT00262249
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia Fractures
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 407
- Registration Number
- NCT00254514
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain
Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT00184639
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 112
- Registration Number
- NCT00184743
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 576
- Registration Number
- NCT00184795
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, WAtford, United Kingdom
Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 98
- Registration Number
- NCT00184717
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
© Copyright 2024. All Rights Reserved by MedPath